Related references
Note: Only part of the references are listed.Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review
Claire Gorry et al.
VALUE IN HEALTH (2020)
Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong
Herbert H. Loong et al.
COST EFFECTIVENESS AND RESOURCE ALLOCATION (2020)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
Cancer incidence and mortality in China, 2014
Wanqing Chen et al.
CHINESE JOURNAL OF CANCER RESEARCH (2018)
Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis
Bin Wu et al.
INFLAMMATORY BOWEL DISEASES (2018)
Cost-effectiveness analysis of pembrolizumab in cancer therapy: A systematic review.
Claudette Donatien et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
Vivek Verma et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal
Luis Silva Miguel et al.
VALUE IN HEALTH (2017)
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Jeffrey E. Gershenwald et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) VERSUS IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA IN CANADA
J. Wang et al.
VALUE IN HEALTH (2016)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR UNRESECTABLE METASTATIC MELANOMA AFTER PROGRESSION WITH IPILIMUMAB IN ENGLAND
E. Marriott et al.
VALUE IN HEALTH (2015)
Chinese Time Trade-Off Values for EQ-5D Health States
Gordon G. Liu et al.
VALUE IN HEALTH (2014)
Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma
Keith T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases
Zhihong Chi et al.
BMC CANCER (2011)
Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trial
Maja A. Hofmann et al.
MELANOMA RESEARCH (2011)
Current systemic therapy for metastatic melanoma
Sanjiv S. Agarwala
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
CM Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
